Serum transthyretin (sTTR) is the precursor protein of wild type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and the biological target of tafamidis. Its role as a prognostic marker in tafamidis-treated ATTRwt-CM is still debated.

Serum transthyretin (sTTR) is the precursor protein of wild type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and the biological target of tafamidis. Its role as a prognostic marker in tafamidis-treated ATTRwt-CM is still debated.

Serum prealbumin and disease progression in patients with wild-type Transthyretin Cardiomyopathy on treatment with Tafamidis.

BALDAN, MARCO
2023/2024

Abstract

Serum transthyretin (sTTR) is the precursor protein of wild type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and the biological target of tafamidis. Its role as a prognostic marker in tafamidis-treated ATTRwt-CM is still debated.
2023
Serum prealbumin and disease progression in patients with wild-type Transthyretin Cardiomyopathy on treatment with Tafamidis.
Serum transthyretin (sTTR) is the precursor protein of wild type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and the biological target of tafamidis. Its role as a prognostic marker in tafamidis-treated ATTRwt-CM is still debated.
cardiomyopathy
Serum prealbumin
Tafamidis
File in questo prodotto:
File Dimensione Formato  
Tesi Baldan Marco.pdf

Accesso riservato

Dimensione 875.99 kB
Formato Adobe PDF
875.99 kB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/97191